BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Head and neck cancer AND EML4, ENSG00000143924, 27436 AND Treatment
8 results:

  • 1. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung cancer Treated With Chemoradiation and Consolidative Durvalumab.
    Liu Y; Zhang Z; Rinsurongkawong W; Gay CM; Le X; Ning MS; Lewis J; Rinsurongkawong V; Lee JJ; Roth J; Swisher S; Gandhi S; Lee PP; Gibbons DL; Vaporciyan AA; Heymach JV; Zhang J; Lin SH
    JAMA Netw Open; 2022 Jun; 5(6):e2215589. PubMed ID: 35666500
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinicopathological and Molecular Features of Secondary cancer (Metastasis) to the Thyroid and Advances in Management.
    Nguyen M; He G; Lam AK
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328664
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Targeting eml4-ALK gene fusion variant 3 in thyroid cancer.
    Aydemirli MD; van Eendenburg JDH; van Wezel T; Oosting J; Corver WE; Kapiteijn E; Morreau H
    Endocr Relat Cancer; 2021 May; 28(6):377-389. PubMed ID: 33878728
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung cancer.
    Horn L; Whisenant JG; Wakelee H; Reckamp KL; Qiao H; Leal TA; Du L; Hernandez J; Huang V; Blumenschein GR; Waqar SN; Patel SP; Nieva J; Oxnard GR; Sanborn RE; Shaffer T; Garg K; Holzhausen A; Harrow K; Liang C; Lim LP; Li M; Lovly CM
    J Thorac Oncol; 2019 Nov; 14(11):1901-1911. PubMed ID: 31446141
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement.
    Dogan S; Ng CKY; Xu B; Kumar R; Wang L; Edelweiss M; Scott SN; Zehir A; Drilon A; Morris LGT; Lee NY; Antonescu CR; Ho AL; Katabi N; Berger MF; Reis-Filho JS
    Hum Pathol; 2019 Jun; 88():66-77. PubMed ID: 30946933
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma.
    van der Tuin K; Ventayol Garcia M; Corver WE; Khalifa MN; Ruano Neto D; Corssmit EPM; Hes FJ; Links TP; Smit JWA; Plantinga TS; Kapiteijn E; van Wezel T; Morreau H
    Eur J Endocrinol; 2019 Apr; 180(4):235-241. PubMed ID: 30668525
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified eml4-ALK translocation as a therapeutic target.
    Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
    World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
    Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.